🟢 Gossamer Bio is trading 7% up today with no clear company-specific catalyst identified

Gossamer Bio is trading 6.89% up at $11.10, with no clearly reported company-specific catalyst identified for September 16, 2026.

• The 1-for-80 reverse stock split became effective September 10.
• The company has planned a September seralutinib NDA submission.
• The move appears more consistent with post-split volatility and speculative trading than the broader biotech sector, which is down 2.11%; available evidence does not establish a definitive cause.